AMLYCAS Trademark

Trademark Overview

On Friday, October 20, 2017, a trademark application was filed for AMLYCAS with the United States Patent and Trademark Office. The USPTO has given the AMLYCAS trademark a serial number of 87653874. The federal status of this trademark filing is REGISTERED as of Tuesday, May 24, 2022. This trademark is owned by Prothena Therapeutics Limited. The AMLYCAS trademark is filed in the Pharmaceutical Products category with the following description:

Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of autoimmune, metastatic, hematologic, oncologic, ocular and neurologic diseases, conditions and disorders; Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders associated with misfolded proteins; Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders affecting the central nervous system; Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of amyloidosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, dermatitis, host and graft rejections, Alzheimer's and Parkinson's-disease associated neuropsychiatric disorders, insulin resistance, metabolic syndrome and diabetes
amlycas

General Information

Serial Number87653874
Word MarkAMLYCAS
Filing DateFriday, October 20, 2017
Status700 - REGISTERED
Status DateTuesday, May 24, 2022
Registration Number6720928
Registration DateTuesday, May 24, 2022
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 9, 2019

Trademark Statements

Goods and ServicesBiopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of autoimmune, metastatic, hematologic, oncologic, ocular and neurologic diseases, conditions and disorders; Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders associated with misfolded proteins; Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders affecting the central nervous system; Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of amyloidosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, dermatitis, host and graft rejections, Alzheimer's and Parkinson's-disease associated neuropsychiatric disorders, insulin resistance, metabolic syndrome and diabetes

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, October 30, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameProthena Biosciences Limited
Party Type30 - Original Registrant
Legal Entity Type77 - NOT AVAILABLE
AddressGrand Canal Docklands, Dublin 2 D02T804
IE
Party NameProthena Biosciences Limited
Party Type21 - New Owner After Publication
Legal Entity Type77 - NOT AVAILABLE
AddressGrand Canal Docklands, Dublin 2 D02T804
IE
Party NameProthena Therapeutics Limited
Party Type20 - Owner at Publication
Legal Entity Type77 - NOT AVAILABLE
AddressDún Laoghaire, Dublin A96T927
IE
Party NameProthena Therapeutics Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDún Laoghaire, Dublin A96T927
IE

Trademark Events

Event DateEvent Description
Tuesday, May 24, 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, May 24, 2022REGISTERED-PRINCIPAL REGISTER
Monday, April 4, 20221(B) BASIS DELETED; PROCEED TO REGISTRATION
Wednesday, March 30, 2022NOTICE OF ALLOWANCE CANCELLED
Wednesday, March 30, 2022TEAS DELETE 1(B) BASIS RECEIVED
Tuesday, December 14, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 13, 2021SOU EXTENSION 5 GRANTED
Thursday, December 2, 2021SOU EXTENSION 5 FILED
Monday, December 13, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, December 2, 2021TEAS EXTENSION RECEIVED
Friday, June 4, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 2, 2021SOU EXTENSION 4 GRANTED
Wednesday, June 2, 2021SOU EXTENSION 4 FILED
Wednesday, June 2, 2021TEAS EXTENSION RECEIVED
Friday, December 4, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 2, 2020SOU EXTENSION 3 GRANTED
Wednesday, December 2, 2020SOU EXTENSION 3 FILED
Wednesday, December 2, 2020TEAS EXTENSION RECEIVED
Friday, November 13, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 12, 2020SOU EXTENSION 2 GRANTED
Thursday, June 4, 2020SOU EXTENSION 2 FILED
Thursday, July 23, 2020PETITION TO DIRECTOR - GRANTED
Thursday, July 23, 2020ASSIGNED TO PETITION STAFF
Thursday, June 18, 2020AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Friday, June 12, 2020TEAS PETITION TO DIRECTOR RECEIVED
Thursday, June 4, 2020TEAS EXTENSION RECEIVED
Thursday, December 5, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 3, 2019SOU EXTENSION 1 GRANTED
Tuesday, December 3, 2019SOU EXTENSION 1 FILED
Tuesday, December 3, 2019TEAS EXTENSION RECEIVED
Tuesday, June 4, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 9, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 9, 2019PUBLISHED FOR OPPOSITION
Wednesday, March 20, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 6, 2019ELECTRONIC RECORD REVIEW COMPLETE
Friday, March 1, 2019ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Wednesday, February 27, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, February 25, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, February 25, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, February 21, 2019TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Sunday, September 2, 2018NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Sunday, September 2, 2018INQUIRY TO SUSPENSION E-MAILED
Sunday, September 2, 2018SUSPENSION INQUIRY WRITTEN
Thursday, August 9, 2018SUSPENSION CHECKED ¿ TO ATTORNEY FOR ACTION
Thursday, August 9, 2018ASSIGNED TO LIE
Friday, January 19, 2018NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, January 19, 2018LETTER OF SUSPENSION E-MAILED
Friday, January 19, 2018SUSPENSION LETTER WRITTEN
Friday, January 19, 2018ASSIGNED TO EXAMINER
Monday, October 30, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, October 24, 2017NEW APPLICATION ENTERED IN TRAM

Related Keywords

amlycas prognosis biopharmaceuticals disorders management diagnosis pharmaceuticals prevention treatment diseases conditions